The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
Two hundred HCC patients with partial hepatectomy were enrolled as a cohort for observational study. The inclusion criterion was intended curative hepatectomy for HCC patients by image analysis, and the exclusion criteria were unresectable disease, synchronous cancers, recurrent cancers, or distant metastasis. The study endpoint was 30 March 2019, and tumor staging was based on the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system for HCC

Detailed Description
-----------------
To determine the role of SOX4 in tumor progression in patients with HCC, we examined SOX4 expression through immunohistochemistry (IHC) staining of 200 formalin-fixed and paraffin-embedded (FFPE) HCC specimens . The SOX4 high group of patients was associated with positive etiology of hepatitis B virus (P = 0.044), tumor size >5 cm (P = 0.014), thrombus formation (P = 0.012), higher microvessel density (MVD) (P = 0.012) in tumor lesions, and distant metastasis (P <0.001). Cox regression analysis showed that patients with elderly age (P <0.001), higher ⍺-fetal protein (AFP) (P = 0.045), presence of cirrhosis (P = 0.008), and SOX4 high in tumor specimen (P = 0.042) were independent risk factors . The SOX4 high group performed significantly worse regarding overall survival (OS) (P = 0.043) and disease-free survival (DFS) (P = 0.019) based on the Kaplan-Meier analysis.

Official Title
-----------------
SOX4 Activates CXCL12 in Hepatocellular Carcinoma Cells to Modulate Endothelial Cell Migration and Angiogenesis in Vivo

Conditions
-----------------
Translational Research of SOX4 in Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Other: microvessel density


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects with pathologic diagnosis of hepatocellular carcinoma and curative partial hepatectomies - Exclusion Criteria: history of different malignant disease, subject cannot be treated with curative surgery -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SOX4 high<br>Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group | Other: microvessel density<br>* the vessel numbers in high power field with Anti-CD31 staining in tumor specimen<br>|
| SOX4 low<br>Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group | Other: microvessel density<br>* the vessel numbers in high power field with Anti-CD31 staining in tumor specimen<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease free survival (DFS) | The length of time from curative hepatectomies and recurrence or mortality | a month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | The length of time from curative hepatectomies and still alive | a month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SOX4, angiogenesis, microvessel density